NCT02399813View on ClinicalTrials.gov

A Phase 2 Study of Axalimogene Filolisbac (ADXS11-001) in Participants With Carcinoma of the Anorectal Canal

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

June 2, 2016

Primary Completion Date

January 3, 2019

Study Completion Date

January 3, 2019

Conditions
Anal CancerRectal Cancer
Interventions
DRUG

Axalimogene filolisbac

Trial Locations (10)

63110

St Louis

77030

Houston

Unknown

Duarte

Indiana University, Indianapolis

Detroit

Buffalo

Durham

Fox Chase, Philadelphia

Nashville

06510

New Haven

Sponsors

Lead Sponsor

Advaxis, Inc.
All Listed Sponsors
lead

Advaxis, Inc.

INDUSTRY

NCT02399813 - A Phase 2 Study of Axalimogene Filolisbac (ADXS11-001) in Participants With Carcinoma of the Anorectal Canal | Biotech Hunter | Biotech Hunter